Passage Bio Stock Discussion

$Passage Bio (PASG.US)$
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Passage Bio (NASDAQ: PASG) has received positive feedback from the FDA on expanding its upliFT-D trial of PBFT02to include FTD-C9orf72 patients. The company plans to amend the ongoing Phase 1/2 global study protocol to introduce this new patient population, with dosing expected to begin in 1H 2025. This expansion is supported by compelling preclin...

$Passage Bio (PASG.US)$ exciting next few weeks ahead 💸💸

$Passage Bio (PASG.US)$ 👀 things heating 🔥 up here if  close above 1.37 we will flying ✈️ parabolic ?

$Passage Bio (PASG.US)$ Passage Bio Announced Initial Safety And Biomarker Data From Three Cohort 1 Patients In The Ongoing Global Phase 1/2 UpliFT-D Trial Of PBFT02, An Adeno-associated Virus-delivery Gene Therapy For Frontotemporal Dementia With Granulin Mutations

Gainers:
• $DBV Technologies (DBVT.US)$ +23.5% (positive topline results from Phase 3 EPITOPE Trial)
• $Aldeyra Therapeutics (ALDX.US)$ +19.2% (achieves primary endpoint in phase 3 tranquility-2 trial)
• $MediciNova (MNOV.US)$ +11.9% (top-line results from phase 2 clinical trial of MN-166)
• $Torrid (CURV.US)$ +11% (In reaction to earnings/guidance)
• $Novavax (NVAX.US)$ +10.1% (FDA advisory committee recommends EUA for its COVID-19 v...

Gainers
- $Consolidated Communications (CNSL.US)$ +14.6%: Searchlight affirms 34.6% active holding; to evaluate the possibility of a further investment in or full acquisition.
- $Voyager Therapeutics (VYGR.US)$ +12.2%: agrees to licensing option with $Novartis AG (NVS.US)$; Voyager receives $54 million upfront.
- $Aegon Ltd (AEG.US)$ +6%: provides update on Russian and Belarusian investments following invasion of Ukraine.
- $AZZ Inc (AZZ.US)$ +...